Sporadic ovarian cancer: the probable model of pathogenesis

Abstract

This article in question dwells on a possible pathogenetic model ovarian cancer, it’s histogenesis speciality, the role of ovulation, chronic inflammation and stem cells. The scheme of two variant of avarian cancer progress and possible ways of prevention it are represented as well

Keywords

ovarian cancer / pathogenesis / ovulation / chronic inflammation / stem cell

References

[1] Аксель Е. М. Статистика злокачественных новообразований женской половой сферы // Онкогинекология. — 2012. — № 1. — С. 18–23.

[2] Глазунов М. Ф. Опухоли яичников. — М.: Медгиз, 1954. — 324 с.

[3] Дорохов И. И. Мезотелий париетальной брюшины человека и изменения его при некоторых заболеваниях. — Л.,1951

[4] Рак женских репродуктивных органов в процессе эволюции / Итон С. Б. [и др.] // Вопр. онкол. — 1991. — № 9–10. — С. 899–907

[5] A case-control study of oral contraceptive use and invasive epithelial ovarian cancer / Rosenberg L. [et al.] // Am. J. Epidemiol. — 1994. — Vol. 139. — P. 654–661.

[6] A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma / Kowalski L. D. [et al.] // Cancer. — 1997. — Vol. 79. — P. 1587–1594.

[7] Altinoz M. A., Korkmaz R. NF-kappaB, mac- rophage migration inhibitory factor and cyclooxyge- naseinhibitions as likely mechanisms behind the acеtaminophen — and NSAID- prevention of the ovarian cancer // Neoplasma. — 2004. — Vol. 51. — P. 239–247.

[8] An epidemiologic case-control study of ovarian cancer and reproductive factors / Nanca P. C. [et al.] // Am. J. Epidemiol. — 1984. — Vol. 119. — P. 705–713.

[9] C-erbB-2 and p53 expression in fallopian tube carcinoma / Lacy M. Q. [et al.] // Cancer. — 1995. — Vol. 75. — P. 2891–2896.

[10] Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US control studies / Whittemore A. S. [et al.] // Am. J. Epidemiol. — 1992. — Vol. 136. — P. 1212–1220.

[11] Edmondson R. J., Monaghan J. M., Davies B. R. The human ovarian surface epithelium is an androgen responsive tissue // Br. J. Cancer. — 2002. — Vol. 86. — P. 879–885.

[12] Follicle stimulating hormone-induced growth promotion and gene ex pression profiles on ovarian surface epithelial cells / Ji Q. [et al.] // Int. J. Cancer. — 2004. — Vol. 112. — P. 803–814.

[13] Genomic alterations in fallopian tube carcinoma: Comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis / Pere H. [et al.] // Cancer Res. — 1998. — Vol. 58. — P. 4274–4276.

[14] Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha (v)-integrin / Schiffenbauer Y. S. [et al.] // Gynecol. Oncol. — 2002. — Vol. 84. — P. 296–302.

[15] Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma / Halperin R. [et al.] // Int. J. Gynecol. Pathol. — 2001. — Vol. 20. — P. 341–345.

[16] Keller Th. L’activite normale et pathologique de l’epithelium germinatif de l’ovaire adalte // Gynecol. Obstet. — 1928. — Vol. 17. — P. 10–39.

[17] Maximov A. A. = Максимов А. А. Die hystologishen Vorgange bei der Heilung von Eierstocksverletzungen und die Regenerationsfahigkeit des Eiertockgewebes // Virch. Arch. — 1900. — S. 160.

[18] Molecular similarities between primary peritoneal and primary ovarian carcinomas / Chen L. M. [et al] // Int. J. Gynecol. Cancer. — 2003. — Vol. 13. — P. 749–755.

[19] Ness R. B., Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer // J. Natl. Cancer Inst. — 1999. — Vol. 91. — P. 1459–1467.

[20] NIH Consensus Development Conference Statement. Ovarian cancer: screening, treatment and Follow-up // Gynecol. Oncol. — 1994. — Vol. 55. — P. 4–14.

[21] Noara H. Developmental vpatterning in the wrong context: The paradox of epithelial ovarian cancers // Cell Cycle. — 2005. — Vol. 4. — P. 1033–1035.

[22] Ovarian cancer risk after the use of ovulation stimulating drugs / Brinton L. A. [et al] // Obstet. Gynecol. — 2004. — Vol. 103. — P. 1194–1203.

[23] Ovarian surface epithelium: biology, endocrinology and pathology / Auersperg N. [et al.] // Endocr. Rev. — 200. — Vol. 122. — P. 225–228.

[24] Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel / Gaspard U. J. [et al.] // Contraception. — 1983. — Vol. 27. — P. 577–590.

[25] Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer / Gwinn M. L. [et al.] // J. Clin. Epidemiol. — 1990. — Vol. 43. — P. 559–568.

[26] Pregnensy recency and risk of ovarian cancer / Cooper G. S. [et al.] // Cancer Caus. Contr. — 1999. — Vol. 10. — P. 397–402.

[27] Primary peritoneal serous papillary carcinoma: A new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer / Halperin R. [et al.] // Int. J. Gynecol. Cancer. — 2001. — Vol. 11. — P. 403–408.

[28] Purdie D. M., Bain C. J., Siskind V. Hormon replacement therapy and the risk of epithelial ovarian cancer // Br. J. Cancer. — 1999. — Vol. 81. — P. 559–564.

[29] Riman T., Persont N. S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence // Clin. Endocrinol. — 1998. — Vol. 49, N 6. — P. 695–707.

[30] Risch H. A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone // J. Natl. Cancer. Inst. — 1998. — Vol. 90. — P. 1774–1786.

[31] Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and independent growth in human ovarian surface epithelial cell lines / Tashiro H. [et al.] // Cancer Sci. — 2003. — Vol. 94. — P. 953–959.

[32] Seeger H., Wallwiener D., Mueck A. O. Is there a protective role of progestogens on the proliferation of human ovarian cancer cells in the presence of growth factors? // Eur. J. Gynaecol. Oncol. –2006. — Vol. 27. — P. 139–141.

[33] Shafer Z. T., Brugge J. S. IL-6 involvement in epithelial cancer // J. Clin. Invest. — 2004. — Vol. 117, N 12. — P. 3660–3663.

[34] Stecca B., Mas C., Ruiz i Altaba A. Interference with HH-GLI signaling inhibits cancer // Trends Mol. Med. — 2005. — Vol. 11, N 5. — P. 199–203.

[35] Tumor inflammatory angiogenesis and its chemoprevation / Albini A. [et al.] // Cancer Res. — 2005. — Vol. 65, N 23. — P. 10637–10641

[36] VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors / Wang J. [et al.] // Int. J. Cancer. — 2002. — Vol. 97. — P. 163–167.

[37] Vessey M., Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004 // Br. J. Cancer. — 2006. — Vol. 95, N 3. — P. 385–389.

[38] Walthard M. Zur Aetiologieder Ovarialadenoma // Ztschr. Geburtsh. Gynak. — 1903. — Vol. 49. — S. 233–329.

RIGHTS & PERMISSIONS

Ashrafyan L.A.